Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SPECT/CT Imaging of Different Types of HER2 Expression in Breast Cancer Using Technetium-99m-labelled Affibody [99mTc]Tc -ZHER2:4107

NCT07292571 is registered in ClinicalTrials.gov with Tomsk National Research Medical Center of the Russian Academy of Sciences as lead sponsor.

NCT NCT07292571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07292571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SPECT/CT Imaging of Different Types of HER2 Expression in Breast Cancer Using Technetium-99m-labelled Affibody [99mTc]Tc -ZHER2:4107
Lead sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
October 20, 2025
Completion date
December 30, 2026
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary breast cancer